Stocks

The market often responds with a “sell the news” reaction after a significant catalyst like a satellite launch. While the launch is a milestone, investors immediately shift their focus to the next phases, including deployment, testing, and commercial rollout. If these subsequent steps are perceived as uncertain or delayed, the stock can fall. In the case of BlueBird 6, the market may have started to price in the complexities of deployment and performance rather than the excitement of the launch.

The stock price of QBTS decreased by 9.54% on December 23, 2025. The decline can be attributed to **insider selling**. On December 22, 2025, CFO John Markovich sold 100,000 shares at an average price of $30.03, reducing his ownership by 6.36% and totaling $3.003 million. Similarly, CEO Alan Baratz sold 793,712 shares at an average price of $30.13, decreasing his stake by 23.16% and amounting to approximately $23.9 million. These sales were disclosed in SEC filings and highlight near-term volatility amid retail trading excitement around D-Wave's CES 2026 commercialization showcase.

The U.S. Department of Justice (DOJ) has subpoenaed Regencell Bioscience, demanding documents and communications related to corporate operational, financial, and accounting matters. This legal uncertainty has been a significant overhang for the company, and the subpoena adds to the existing legal costs and potential fines or penalties.

The FDA approval of Wegovy pill as the first once-daily oral semaglutide makes it a groundbreaking development in the chronic weight management sector. This addresses a key barrier to treatment adoption, as many patients avoid injectable medications due to needle aversion or inconvenience. The convenience factor is a major driver for the expansion of the market, as it caters to a broader patient pool that prefers oral medications.